Interrelation of fibroblast growth factor 19 with the bile acids’ levels and lipid profile parameters in patients with chronic non-calculous cholecystitis with and without type 2 diabetes mellitus

2020 ◽  
Vol 0 (2) ◽  
pp. 30-36
Author(s):  
L. V. Zhuravlyova ◽  
G. Yu. Tymoshenko
2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Akio Nakashima ◽  
Keitaro Yokoyama ◽  
Daiji Kawanami ◽  
Ichiro Ohkido ◽  
Mitsuyoshi Urashima ◽  
...  

Author(s):  
P. Divya ◽  
R. Inmozhi Sivakamasundari ◽  
T. K. Jithesh ◽  
K. Santha ◽  
K. Shifa ◽  
...  

Background: Diabetes mellitus is rising all over the world due to population growth, aging, urbanisation, and the increase of obesity due to physical inactivity, characterized by persistent high blood glucose levels associated with aberrations in lipid, carbohydrate, and protein metabolisms leading to water and electrolyte imbalance. Cardiovascular diseases are the leading causes of mortality in diabetic patients. Mechanisms such as oxidative stress, lipid metabolism imbalance, as well as myocardial cell apoptosis are key factors to facilitate the progression of Diabetic cardiomyopathy. Aim: The aim of this study was to assess FGF-21 levels and their association with lipid profile parameters and oxidative stress in patients with type 2 diabetes mellitus. Methods: A patient based cross-sectional study was conducted among the subjects with history of type 2 DM for the past 10 years. Results: Variations in FBS, T.C, TG, LDL, HDL, VLDL, FGF-21, MDA and AOPP levels among cases and controls were depicted in Table 2. There was an increase in all these parameters in cases compared to controls whereas HDL showed a decrease among cases. Conclusion: Our study concluded that there is a significant correlation between fibroblast growth factor 21 (FGF-21), oxidative stress, and abnormal lipid profile in type 2 diabetic patients. We would recommend further studies to explore the role of FGF21 as an important marker in predicting cardiovascular risk in diabetic patients.


2009 ◽  
Vol 161 (3) ◽  
pp. 391-395 ◽  
Author(s):  
Ke Li ◽  
Ling Li ◽  
Mengliu Yang ◽  
Haihong Zong ◽  
Hua Liu ◽  
...  

ObjectiveFibroblast growth factor-21 (FGF-21) has recently been characterized as a potent metabolic regulator, but its pathophysiologic roles in humans remain unknown. This study aimed to investigate the effects of rosiglitazone on plasma FGF-21 levels in patients with type 2 diabetes mellitus (T2DM).Design and methodsThirty patients with new-onset T2DM (nT2DM), 34 type 2 diabetic patients with poor glycemic control (pT2DM) after the treatment with single hypoglycemic agent metformin, and 30 sex- and age-matched normal glycaemic controls (NGT) participated in the study. The pT2DM group was treated with rosiglitazone for 12 weeks. Plasma FGF-21 levels were measured with a RIA. The relationship between plasma FGF-21 levels and metabolic parameters was also analyzed.ResultsFasting plasma FGF-21 levels were higher in nT2DM and pT2DM groups than in the control (1.81±0.64 vs 1.87±0.63 vs 1.52±0.61 μg/l, P<0.05), but there was no difference between nT2DM and pT2DM groups. Fasting plasma FGF-21 levels were decreased significantly in pT2DM group after the treatment with rosiglitazone compared with pre-treatment (1.59±0.63 vs 1.87±0.64 μ/l, P<0.05). In all diabetic patients, multiple regression analysis showed that HbA1c, fasting insulin, and homeostasis model assessment-insulin resistance index were independently associated with plasma FGF-21 levels.ConclusionsIn pT2DM patients, plasma FGF-21 levels are increased, but significantly decreased after the treatment with rosiglitazone on top of ongoing metformin therapy. These data suggest that rosiglitazone may play a role in lowering FGF-21 levels in T2DM patients.


Sign in / Sign up

Export Citation Format

Share Document